Document is current
Any future updates will be listed below
-
Authors
Morgan, Christopher Llewellyn https://orcid.org/0000-0001-8796-7406
Godfrey, Josie
Chandler, Fleur
Reuben, Emily
Currie, Craig J.
-
Funding
Funding for this research was provided by:
Duchenne UK
- License Information
-
More Information
Article History
Received: 21 October 2023
Accepted: 15 May 2024
First Online: 12 August 2024
Declarations
:
: CPRD has ethics approval from the Health Research Authority to support research using anonymised patient data (IRAS ID 242149). CPRD Research Data Governance (RDG) approval was granted for this study (21_000470).
: Not applicable.
: CJJ is the founder, and CLlM is an employee, of Human Data Sciences, a research consultancy that receives funding from many organisations including the pharmaceutical industry. Human Data Sciences received funding from Duchenne UK to conduct this study.FC is employed by Sanofi UK (although they have no DMD therapy in their portfolio or pipeline) and has shares in Shares in GSK and Sanofi. She is chair of Project HERCULES, which is funded by multiple pharmaceutical companies, but receives no payment.Josie Godfrey receives payments from Duchenne UK for acting as Strategic Director of Project HERCULES which is funded by multiple pharmaceutical companies.Emily Reuben OBE is the Chief Executive Officer of Duchenne UK.
